1. Spain Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
LABORATORIO REIG JOFRE, S.A.

LABORATORIO REIG JOFRE, S.A.

2.58
EUR
-0.02
(-0.77%)
0.09EPS
32.23P/E
220.77MMarket Cap
Nov 13Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.93
2.43
0.17
2.56
2.57
2.74
2.81
2.99
3.03
3.44
3.95
4.23
4.07
4.9
Basic EPS, GAAP
0.06
0.17
0.01
0.12
0.14
0.14
0.07
0.07
0.07
0.1
0.12
0.13
0.06
0.08
Free Cash Flow per Basic Share
-0.01
-0.79
- -
-0.22
0.05
-0.1
-0.27
0.09
-0.07
0.06
0.08
0.13
-0.21
- -
Dividend per Share
0.74
0.06
- -
- -
- -
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4.6
1.88
2
2.12
2.22
2.31
2.35
2.42
2.46
2.51
2.59
2.67
2.68
2.69
Tangible Book Value per Share
0.98
0.96
1.08
1.16
1.27
1.28
0.83
0.94
1.06
1.22
1.44
1.65
1.5
1.45
Basic Weighted Avg Shares
16
14
929
63
65
66
71
77
78
79
80
80
81
83
Sales/Revenue/Turnover
31
33
157
161
168
180
200
230
236
271
316
339
331
407
Operating Margin (%)
6.98
8.37
7.46
6.07
5.37
4.89
3.39
4.28
3.96
3.4
3.93
4.45
2.05
3.3
Depreciation Expense
1
1
5
6
7
8
13
17
18
21
23
23
25
31
Net Income, GAAP
1
2
9
8
9
9
5
6
5
8
9
10
5
7
Effective Tax Rate (%)
54.47
9.29
20.51
35.9
- -
2.44
6.86
11.83
12.31
7.51
10.47
11.46
20.92
13.83
Profit Margin (%)
3.04
6.94
5.58
4.76
5.26
5.13
2.47
2.47
2.16
2.99
2.98
3.06
1.52
1.7
Working Capital
6
31
34
51
47
43
28
23
34
37
42
68
54
59
LT Debt
- -
12
10
17
17
21
42
43
49
37
23
37
58
69
Total Equity
76
118
126
133
142
150
178
184
189
195
204
214
220
223
Return on Invested Capital (%)
1.11
2.31
6.53
4.89
- -
5.78
2.86
3.38
3.08
3.04
3.62
4.13
1.12
2.43
Return on Capital (%)
1.21
2.3
6.51
5.26
- -
5.78
2.71
2.64
2.29
3.42
3.93
4.22
2.1
2.5
Return on Common Equity (%)
1.17
2.38
7.18
5.93
6.42
6.36
3.01
3.13
2.73
4.23
4.72
4.96
2.32
3.17

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
33
36
51
LT Borrowings
43
51
53
LT Finance Leases
15
16
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
81
81
82
Market Capitalization
209
200
221

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
155
169
173
Cash, Cash Equivalents & STI
17
22
15
Accounts Receivable, Net
67
69
73
Inventories
61
69
75
Total Current Liabilities
101
109
114
Payables & Accruals
- -
- -
- -
ST Debt
33
36
51
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.88%
3.63%
3.04%
Free Cash Flow
-155.27%
-105.91%
-259.04%
Net Income, GAAP
-0.05%
4.75%
-51.64%
Sales/Revenue/Turnover
7.92%
7.79%
-2.3%
Total Cash Common Dividend
90.21%
-14.96%
28%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
86
86
80
166
339
2025
88
79
75
164
331
2026
86
82
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.03
0.03
0.06
0.13
2025
0.05
-0.03
- -
0.04
0.06
2026
0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ignasi Biosca Reig
Full Time Employees
1,512
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Gran Capita, 10 Barcelona CT Spain 08970
IPO Date
Nov 7, 2006
Website
reigjofre.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Laboratorio Reig Jofre, S.A. Laboratorio Reig Jofre, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products, food supplements, and related healthcare offerings; its core products encompass beta-lactam antibiotics including penicillanic and cephalosporin formulations in vials, oral dosages, sachets, and syrups, sterile injectables and lyophilizates such as analgesics, specialty pharmacare items for skin, hair, nails, joint health, pain management, and women's health under brands like Reig Jofre, Medea, Orravan, Bioglan, and Sala, nutritional supplements via Forté Pharma, dermatological cosmetics and semisolids, oral solids including capsules, tablets, and lozenges, liquids such as syrups and topical solutions, and medical devices; the company provides CDMO and CMO services featuring aseptic fill-finish, analytical development, regulatory support, and production of complex molecules like peptides and biologics using QbD methodologies, with capabilities certified by EMA, FDA, PMDA, Health Canada, and ANVISA. Founded in 1929 and headquartered in Sant Joan Despí, Barcelona, Spain, with manufacturing facilities in Barcelona and Toledo, Spain, and Malmö, Sweden, it operates subsidiaries in Spain, France, Portugal, Belgium, Sweden, United Kingdom, Poland, Czech Republic, and Singapore, alongside over 155 partners across more than 70 countries in Europe, Africa, the Americas, Australia, and Asia, employing over 1,100 people across four production centers. Recent developments include the opening of a Czech Republic subsidiary in September 2024, a partnership with LEO PHARMA in March 2025 to enhance psoriasis treatment access in primary care, the launch of Vincobiosis® Acneic for acne-prone skin in February 2025, a €5.8 million investment in Leanbio in April 2024 for biotechnological vertical integration, joining the IBEX SMALL CAP INDEX in June 2024, participation as an associated partner in the Med4Cure project for advanced therapies in May 2024, and reporting €242 million in nine-month 2025 revenues amid ongoing industrial and biotech transformation.